A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 33/24 (2006.01) A61K 31/555 (2006.01) A61K 39/008 (2006.01)
Patent
CA 2386759
The present invention relates to the use of peroxometallic compounds, such peroxovanadium compounds, to prevent angiogenesis, restenosis and the production of endothelins, as immunomodulators and as antitumorigenic agents. Peroxometallic compounds are preferred since they are more potent, and less toxic, than their "oxo" counterparts, as exemplified by specific peroxovanadium compounds. Anti-angiogenic activity was verified in vitro against human umbilical vascular endothelial cells (HUVECs) as well as ex ovo using the chicken chorioallantoic assay membrane and in the rat aortic ring model and a Matrigel assay in vivo. Peroxovanadium compounds also decrease basal levels and inhibit the increase in plasma endothelins occurring following insulin induction in rats. It is proposed that peroxovanadium compounds are therapeutically-active anti-angiogenics and useful in preventing vascular restenosis by acting, inter alia, by inhibiting one or several protein tyrosine phosphatases (PTPs) involved in the proliferation, differentiation and migration of cells or the secretion of peptides (such endothelins and immunomodulators), or both. These compounds have also been found to be suitable as antitumorigenic agents in the treatment of cancer, such as breast cancer and prostate cancer.
Battistini Bruno Joseph
Doillon Charles
Faure Robert
Olivier Martin
Posner Barry
Goudreau Gage Dubuc
Universite Laval
University Mcgill
LandOfFree
Therapeutic uses of peroxometallic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic uses of peroxometallic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic uses of peroxometallic compounds will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1709358